PDSB - PDS Biotechnology Corp (PDSB) - As PDS0101 Trials Continue Preparations For Pivotal Studies Begin.

Quarterly Loss Was Less Than We Estimated. PDS Biotech reported 2Q22 loss of $5.8 million or $(0.20) per share, beating our estimated loss of $8.8 million or $(0.34) per share. The differences were largely due to R&D expense of $3.7 million compared with our estimate of $5.3 million, as well as a $1.2 million tax benefit. The company ended the quarter with $53.0 million in cash.As The Versatile-002 Trial Continues, Phase 3 Planning Begins. The Phase 2 Versatile-002 trial, testing PDS0101 in combination with the checkpoint inhibitor Keytruda, received a positive opinion from its independent Data Safety Monitoring Board. The recommendation was to continue the trial to completion without any changes to the protocol. In June, the combination of PDS0101 with Keytruda received Fast-Track designation from the FDA. Read More >>